Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Zacks Research

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks reports.

A number of other equities research analysts also recently weighed in on ARCT. Roth Capital restated a “buy” rating and issued a $41.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, September 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Thursday, October 15th. Citigroup raised shares of Arcturus Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $8.00 to $20.00 in a research note on Thursday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 24th. Finally, BTIG Research cut their target price on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $24.50.

Get Our Latest Research Report on ARCT

Arcturus Therapeutics Stock Down 2.2%

NASDAQ:ARCT opened at $7.43 on Thursday. The stock’s 50-day simple moving average is $11.72 and its 200 day simple moving average is $9.10. Arcturus Therapeutics has a twelve month low of $5.50 and a twelve month high of $17.96.

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.43. The firm had revenue of $18.30 million during the quarter, compared to the consensus estimate of $8.00 million. Arcturus Therapeutics had a negative return on equity of 46.79% and a negative net margin of 285.92%. As a group, sell-side analysts predict that Arcturus Therapeutics will post -2.94 EPS for the current year.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Arcturus Therapeutics in the 2nd quarter valued at $17,566,000. Heartland Advisors Inc. purchased a new position in Arcturus Therapeutics in the second quarter valued at approximately $1,474,000. Bank of New York Mellon Corp bought a new stake in Arcturus Therapeutics in the 2nd quarter valued at about $540,000. Hsbc Holdings PLC purchased a new stake in shares of Arcturus Therapeutics during the 2nd quarter valued at approximately $394,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Arcturus Therapeutics during the second quarter worth $229,000. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

(Get Free Report)

Arcturus Therapeutics Holdings Inc. is a biotechnology company founded in 2013 and headquartered in San Diego, California. It develops RNA medicines and vaccines, using its LUNAR lipid-mediated delivery technology and self-amplifying RNA platform to deliver genetic instructions to cells. The company’s pipeline includes investigational treatments for rare diseases, such as ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency. It has also developed ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved in Japan as Kostaive, and works with partners on the development and commercialization of its products.

See Also

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.